MX2010009999A - Derivados de amidas del acido 3-trifluorometil-pirazina-2-carboxil ico como agentes para aumentar el colesterol de lipoproteinas de alta densidad. - Google Patents

Derivados de amidas del acido 3-trifluorometil-pirazina-2-carboxil ico como agentes para aumentar el colesterol de lipoproteinas de alta densidad.

Info

Publication number
MX2010009999A
MX2010009999A MX2010009999A MX2010009999A MX2010009999A MX 2010009999 A MX2010009999 A MX 2010009999A MX 2010009999 A MX2010009999 A MX 2010009999A MX 2010009999 A MX2010009999 A MX 2010009999A MX 2010009999 A MX2010009999 A MX 2010009999A
Authority
MX
Mexico
Prior art keywords
hdl
pyrazine
trifluoromethyl
carboxylic acid
acid amide
Prior art date
Application number
MX2010009999A
Other languages
English (en)
Inventor
Paul Hebeisen
Stephan Roever
Constantinos G Panousis
Matthew Wright
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2010009999A publication Critical patent/MX2010009999A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

La presente invención se refiere a derivados de pirazina de la fórmula (I) en donde R1 a R8 son tal y como se definen en la descripción y las reivindicaciones, para la preparación de medicamentos para el tratamiento y/o profilaxis de enfermedades que pueden tratarse con agentes para aumentar el colesterol HDL, tal como preferiblemente dislipemia.
MX2010009999A 2008-03-31 2009-03-23 Derivados de amidas del acido 3-trifluorometil-pirazina-2-carboxil ico como agentes para aumentar el colesterol de lipoproteinas de alta densidad. MX2010009999A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08153802 2008-03-31
PCT/EP2009/053344 WO2009121741A1 (en) 2008-03-31 2009-03-23 3-trifluoromethyl-pyrazine-2-carboxylic acid amide derivatives as hdl-cholesterol raising agents

Publications (1)

Publication Number Publication Date
MX2010009999A true MX2010009999A (es) 2010-09-30

Family

ID=40585575

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010009999A MX2010009999A (es) 2008-03-31 2009-03-23 Derivados de amidas del acido 3-trifluorometil-pirazina-2-carboxil ico como agentes para aumentar el colesterol de lipoproteinas de alta densidad.

Country Status (14)

Country Link
US (1) US8088920B2 (es)
EP (1) EP2271632B1 (es)
JP (1) JP5243596B2 (es)
KR (1) KR101307066B1 (es)
CN (1) CN101981015B (es)
AR (1) AR071111A1 (es)
AU (1) AU2009231376A1 (es)
CA (1) CA2718645A1 (es)
ES (1) ES2408961T3 (es)
IL (1) IL208022A0 (es)
MX (1) MX2010009999A (es)
PE (1) PE20091711A1 (es)
TW (1) TW200944514A (es)
WO (1) WO2009121741A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101107896B1 (ko) * 2006-10-04 2012-01-25 에프. 호프만-라 로슈 아게 고 밀도 지단백질(ｈｄｌ)-콜레스테롤 상승제로서 3-피리딘카복스아마이드 및 2-피라진카복스아마이드 유도체
WO2012031817A1 (en) * 2010-09-09 2012-03-15 F. Hoffmann-La Roche Ag Determination of abca1 protein levels in cells
US8410107B2 (en) 2010-10-15 2013-04-02 Hoffmann-La Roche Inc. N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US8669254B2 (en) 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9403808B2 (en) * 2011-10-28 2016-08-02 Hoffmann-La Roche Inc. Pyrazine derivatives

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4293552A (en) * 1978-02-27 1981-10-06 Eli Lilly And Company Novel 1-(mono-o-substituted benzoyl)-3-(substituted pyrazinyl) ureas
IL159897A0 (en) * 2001-07-19 2004-06-20 Cv Therapeutics Inc Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
MX2007012213A (es) 2005-04-06 2007-12-10 Hoffmann La Roche Derivados de piridin-3-carboxamida como agonistas inversos de canabinoides.
US7629346B2 (en) 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
US7781593B2 (en) * 2006-09-14 2010-08-24 Hoffmann-La Roche Inc. 5-phenyl-nicotinamide derivatives
KR101107896B1 (ko) * 2006-10-04 2012-01-25 에프. 호프만-라 로슈 아게 고 밀도 지단백질(ｈｄｌ)-콜레스테롤 상승제로서 3-피리딘카복스아마이드 및 2-피라진카복스아마이드 유도체
DE602007006531D1 (de) * 2006-10-04 2010-06-24 Hoffmann La Roche Pyrazin-2-carboxamid-derivate als cb2-rezeptormodulatoren

Also Published As

Publication number Publication date
US8088920B2 (en) 2012-01-03
TW200944514A (en) 2009-11-01
EP2271632A1 (en) 2011-01-12
CN101981015B (zh) 2013-08-21
CN101981015A (zh) 2011-02-23
JP5243596B2 (ja) 2013-07-24
KR20100119819A (ko) 2010-11-10
CA2718645A1 (en) 2009-10-08
US20090247550A1 (en) 2009-10-01
AU2009231376A1 (en) 2009-10-08
JP2011516445A (ja) 2011-05-26
PE20091711A1 (es) 2009-11-13
WO2009121741A1 (en) 2009-10-08
ES2408961T3 (es) 2013-06-24
AR071111A1 (es) 2010-05-26
EP2271632B1 (en) 2013-04-17
KR101307066B1 (ko) 2013-09-11
IL208022A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
TN2012000249A1 (en) Pyrazine derivatives and their use in the treatment of neurological disorders
MX2013002660A (es) Heteroarilmetilamidas.
IN2015DN01156A (es)
PH12015500274A1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
MX2013003634A (es) Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
MY155517A (en) Heterocyclic derivatives
IN2012DN02081A (es)
MX343706B (es) Derivados heterocíclicos novedosos.
MX347596B (es) Derivados de purina para el tratamiento de infecciones viricas.
NZ597517A (en) 5-fluoropyrimidinone derivatives
IN2014KN02601A (es)
NZ708928A (en) Mannose derivatives for treating bacterial infections
MY188960A (en) Cyclic boronic acid ester derivatives and therapeutic uses thereof
IN2012DN00971A (es)
IN2012DN01453A (es)
MX2013004759A (es) Compuestos de oxima como agentes de elevacion de colesterol de lipoproteina de alta densidad (hdl).
MA32544B1 (fr) Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
MX342947B (es) Tratamiento de diabetes tipo 2.
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
MX2014015884A (es) Compuestos antivirales.
NZ597570A (en) N1-acyl-5-fluoropyrimidinone derivatives
MX2010009999A (es) Derivados de amidas del acido 3-trifluorometil-pirazina-2-carboxil ico como agentes para aumentar el colesterol de lipoproteinas de alta densidad.
MY164998A (en) Isoquinolinone derivatives as nk3 antagonists
IN2012DN00763A (es)
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.

Legal Events

Date Code Title Description
FG Grant or registration